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Abstract 
Current focus in colorectal cancer management is on reducing overall colorectal cancer 
mortality by increasing the number of early stage cancers diagnosed and treated with curative 
intent.  There is good evidence that screening for colorectal cancer increases the number of 
early-stage cancers diagnosed and leads to a reduction of cancer specific mortality.  Despite 
the success of the colorectal cancer screening programme in down-staging colorectal cancer, 
interval cancer rates are substantial and other strategies to reduce colorectal cancer risk and 
disease recurrence after surgery with curative intent are desirable. 
Sporadic colorectal cancer appears to be largely associated with lifestyle factors 
including several dietary components, alcohol and tobacco consumption and sedentary 
lifestyle.  Dietary and lifestyle interventions are an attractive option since they are likely to 
produce other beneficial effects on health.  The concept that a diet high in fruit and 
vegetables lowers the risk of colorectal cancer has been in existence for over 40 years.  
Polyphenols are phytochemicals that are ingested as part of a normal diet and which are 
abundant in plant foods including fruits, vegetables and berries. These may, in part, exert 
their anti-carcinogenic effects via the modulation of inflammatory pathways involved in the 
initiation and progression of carcinogenesis, since inflammation has recently been recognised 
as the seventh hallmark of cancer.  Therefore, key signal transduction pathways are likely to 
be fundamental to the association of inflammation and disease progression and the most 
studied of these in colorectal cancer are those mediated via cyclo-oxygenase, PI3K, NF-κB 
and STAT. 
The aim of the present review was to examine the evidence for the effect of dietary 
polyphenols intake on both the tumour and host inflammatory responses, in order to 
determine if polyphenols may be effective as part of a dietary intervention in the context of a 
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colorectal cancer screening programme.  There is now good epidemiological evidence of a 
reduction in colorectal cancer risk from a number of case-control and cohort studies, which 
have assessed the relationship between dietary polyphenol intake and colorectal cancer or 
adenoma formation.  Furthermore, there is limited evidence that polyphenols may exert their 
anti-carcinogenic effects through their anti-inflammatory properties and their effect on signal 
transduction pathways involving COX, PI3k, NF-κB and STAT.  Much of the current 
research concentrates on isolated flavonoids with no recommendation of dose and therefore it 
would be premature to suggest a major public health intervention to promote their 
consumption. However, dietary change is both safe and feasible and this emphasises the need 
for further investigation of dietary polyphenols and their association with colorectal cancer 
risk.  
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Introduction 
Colorectal cancer (CRC) is the 2
nd
 most common cause of cancer-related death in the 
UK (2010) accounting for around 10% of all cancer deaths with 41,000 new cases diagnosed 
per year in the UK and  16,000 deaths (UK CR. Bowel cancer statistics: Cancer Research 
UK. Available from: http://info.cancerresearchuk.org/cancerstats/types/bowel/mortality.  
Only a small percentage (5-10%) of cases of colorectal cancer arise in patients with known 
hereditary syndromes (Park et al., 2013) while the majority of cases are sporadic, arising due 
to multiple alterations and mutations promoting initiation and progression of the dysplasia-
cancer sequence (Fearon, 2011b).  
One strategy to improve outcomes is to focus on reducing overall colorectal cancer 
mortality by increasing the number of early stage cancers diagnosed and treated with curative 
intent, therefore reducing cancer specific mortality.  For example, with current standard 
treatment, reported 5 year survival rates for stages TNM I, II, III and IV disease are 93%, 
77%, 48% and 7% respectively.  There is good evidence that screening for colorectal cancer 
increases the number of early-stage cancers diagnosed and the number of precancerous 
adenomas removed and as a result leads to a reduction of cancer specific mortality (Johnson 
et al., 2010, Ellul et al., 2010).  There was an overall reduction of colorectal cancer mortality 
of 25% in those who took up testing based on biennial screening (Hewitson et al., 2007).    
Despite the success of the colorectal cancer screening programme in down-staging 
colorectal cancer, interval cancer rates are still substantial accounting for 31.2% of cancers 
diagnosed in the screened population in the 1
st
 round in Scotland, 47.7% in the second round 
and 58.9% in the third (Steele et al., 2012).  With the shift to diagnosis at an earlier stage, a 
new focus on prevention of recurrence of colorectal cancer is of considerable interest and 
therefore, other strategies to reduce colorectal cancer risk and disease recurrence after surgery 
with curative intent are desirable.   
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Sporadic colorectal cancer appears to be largely associated with lifestyle factors 
including several dietary components, alcohol and tobacco consumption and sedentary 
lifestyle (Theodoratou et al., 2014, Park et al., 2012, Chan et al., 2011). The evidence for 
these associations is convincing, with a 10% decreased risk of CRC per 10g/day increase in 
intake of dietary fibre, 41% increased risk of CRC for the groups that drank the most alcohol 
in one large analysis of CRC cases (Cho et al., 2004),  38% increased risk of CRC for an 
increase of 40 cigarettes/day (Liang et al., 2009)  and an 11% decreased risk of CRC and 
12% decreased risk of colon cancer per 30 minutes/day of physical activity (WCRF, 2011).  
Since colorectal cancer develops from a precursor lesion, with approximately 8% of polyps 
greater than 1cm developing into cancer at 10 years (Stryker et al., 1987), there is the 
potential advantage that lifestyle interventions may alter the natural history of the disease.  
Patients with polyps are at an increased risk of developing further polyps and therefore a 
higher risk of subsequently developing colorectal cancer (Cairns et al., 2010).   
Only a few studies investigate the relationship between diet and CRC recurrence; 
however patients diagnosed with CRC have been shown to be motivated to adjust their 
dietary and physical activity levels after diagnosis (Patterson et al., 2003, Reedy et al., 2005).  
Dietary and lifestyle interventions are an attractive option since they are likely to lead to 
other beneficial effects on health and these may, in part, exert their anti-carcinogenic effects 
via the modulation of inflammatory pathways involved in the initiation and progression of 
colorectal carcinogenesis. 
The concept that diet may influence colorectal cancer risk is not new; initial 
observations of the relative rarity of colorectal cancers in African populations that consume a 
high fibre diet has been published for over 40 years (Burkitt, 1969).  Red meat intake has also 
been implicated as a risk factor for CRC and many epidemiological studies associate an 
increase in colon cancer or adenoma risk with greater intake of red meat. In the EPIC study, 
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the absolute risk of developing CRC within 10 years for a 50 year old participant was 1.71% 
for the highest category of red and processed meat intake and 1.28% for the lowest category 
(Norat et al., 2005).  A recent prospective study of > 500,000 individuals from 10 European 
populations in the EPIC study showed a 40% reduced risk of CRC with the highest intake of 
fibre and high fruit and vegetable intake was associated with a modest risk reduction 
(Bingham et al., 2003).   Polyphenols / phenolics have recently attracted attention as potential 
agents in the modification of inflammation in early stage colorectal cancer and given that 
inflammation has been identified as the seventh hallmark of cancer, this may be one 
mechanism by which they may reduce colorectal cancer risk.  There is evidence of their 
effect on inflammation-associated pathways and they have low toxicity profiles compared 
with current anti-inflammatory medications.  Therefore, the aim of the present review was to 
examine the evidence for the effect of dietary polyphenols on both the tumour and host 
inflammatory signal transduction pathways in order to determine if polyphenols may be 
effective as part of a dietary intervention in the context of a colorectal cancer screening 
programme. 
 
Inflammation in colorectal cancer 
Inflammation has recently been recognised as the seventh hallmark of cancer and 
current evidence suggests a role for inflammation in the pathogenesis (Colotta et al., 2009) 
and progression of CRC (Hanahan and Weinberg, 2011).  In sporadic colorectal cancer, an 
accumulation of mutations in oncogenes and tumour suppressor genes such as adenomatous 
polyposis coli (APC) and β-catenin promotes the transition from dysplastic crypt foci to 
adenoma and subsequent aberrant genetic alterations including loss of p53 function and K-
Ras activation encourage progression to colorectal carcinoma (Fearon, 2011a).  Inflammation 
also has a significant role to play in influencing this process (Terzic et al., 2010, Pages et al., 
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2010): progression to neoplasia is dependent on growth and pro-survival signals from the 
tumour microenvironment, secreting factors that recruit inflammatory cells and activate 
stromal cells.   
Ongoing inflammation may be driven by cytokines and chemokines secreted by tumour 
cells and mast cells, macrophages and B and T cells, which are recruited to the tumour 
microenvironment.  Alterations in cytokine production accompany the development of CRC, 
polarising from a Th1 type response to a Th2 type response as the tumour progresses along 
the adenoma-carcinoma sequence (Cui and Florholmen, 2008).  Furthermore, there is a strong 
association between the duration and extent of mucosal inflammation in inflammatory bowel 
disease and the development of colorectal cancer.  In keeping with this concept, the overall 
risk of colorectal cancer in those with IBD has decreased markedly in the past few decades 
and this may be a result of improved therapies and better control of colonic inflammation 
associated with the disease (Jess et al., 2012).   
Key components of both local and systemic cancer-related inflammation involve the innate 
immune response and include tumour necrosis and infiltration with neutrophils and 
macrophages and pro-inflammatory cytokines such as IL-6, IL-1, TNF-α, EGF and VEGF, 
which may lead to angiogenesis, cell proliferation and tumorigenesis (Knupfer and Preiss, 
2010, Roxburgh and McMillan, 2012). Key signal transduction pathways are likely to be 
fundamental to the association of inflammation and disease progression in colorectal cancer 
(Figure 1) and in particular, the activation of cyclo-oxygenase, PI3K, NF-κB and STAT 
pathways in the tumour cells and their microenvironment (stroma and inflammatory cell 
infiltrate).  
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NF-kB  
NF-κB is a family of dimers that are regulators of infection and inflammation and have 
been identified as a key component of the signal transduction pathways that occur when 
inflammation progresses to malignancy (Lu et al., 2006).  Under normal resting conditions, 
NF-κB resides in the cytoplasm until it is activated to translocate to the nucleus, where it is 
involved in the expression of genes which suppress apoptosis, induce cellular transformation, 
proliferation, invasion, metastasis, chemo- and radio-resistance and inflammation (Aggarwal 
and Shishodia, 2006).  There are multiple factors that are known to activate the NF-κB 
pathway including inflammatory stimuli, cytokines, viruses and carcinogens.  The resulting 
Systemic Inflammatory Response  
Myeloid cells                                                  
Myeloid-derived suppressor cells 
Metastatic Environment 
Liver                                                             
Lung  
Tumour Microenvironment (Local)     
Peritumoural inflammatory response                     
Tumour necrosis                                           
Early Stage CRC 
Survival 
COX 
STAT3 NF-κB 
PI3K 
Figure 1: The inflammatory response promotes tumour development and progression, and tumour development and 
progression induces the inflammatory response. Local and systemic inflammatory states and the mediators released 
enhance metastogenesis. Furthermore, tumour progression and metastasis promotes the local and systemic inflammatory 
response (Mantovani et al., 2008, Chechlinska et al., 2010).  This vicious circle can be interrupted by various agents and 
there has been recent interest in their administration with the aim of attenuating the inflammatory response associated 
with carcinogenesis, slowing progression or preventing recurrence and therefore potentially improving survival.  
-Polyphenols 
-Other dietary agents e.g. butyrate 
-Drugs e.g. NSAIDs, statins, β-blockers 
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activation of target genes such as cyclin D1, apoptosis suppressor proteins (Bcl-2/Bcl-XL), 
MMP, VEGF and IL-6 may be critical in the development of aggressive cancers (Aggarwal 
and Shishodia, 2006).  NF-κB has effects on both tumour cells and tumour associated 
inflammatory cells and therefore, NF-κB has become a target in the development of novel 
strategies to prevent and treat cancer (Sarkar and Li, 2008).  It has been shown to be activated 
to a greater degree in colorectal tumour specimens than in normal tissue and the degree of 
activation increased with stage of cancer (Kojima et al., 2004).  
 
STAT 
Signal transducer and activator of transcription (STAT) proteins are transcription 
factors.  They prevent apoptosis, therefore encouraging cell survival and growth through 
increased expression of Bcl-2 and Bcl-X (Aggarwal and Shishodia, 2006).  STAT3 is 
activated by many growth factors and cytokines including IL-11, IL-22, EGF, TGF-α or 
PDGF receptors (Yu et al., 2009).  Once activated, STAT3 induces expression of anti-
apoptotic genes, proliferative genes such as Cyclin D1 or c-Myc and vascular endothelial 
growth factor (VEGF) which is responsible for angiogenesis (Terzic et al., 2010). In the 
tumour cells themselves, STAT3 inhibits apoptosis by up-regulating pro-survival Bcl-2 
proteins (Norat et al., 2014, Inoue-Choi et al., 2013).  Furthermore, STAT3 induces tumour-
associated inflammation by upregulating chemokines capable of attracting immune and 
inflammatory cells that further enhance STAT3 activity through the production of IL-6, IL-11 
and other cytokines (Yu et al., 2009).  
 In this way, STAT3 has the ability to control and shape the tumour micro-environment.  
Activation of STAT3 can also lead to prolonged activation of NF-κB, therefore tumour 
promotion and metastasis (Lee et al., 2009).  Studies have suggested that STAT3 activation in 
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colorectal cancer is increased and this was in a stage specific manner, with more STAT3 
identified in the poorly differentiated tumours as well as those of a more progressed T-stage 
(Baral et al., 2009, Park et al., 2008).  
 
PI3k 
Phosphatidylinositol 3-kinase (PI3K) signalling pathways serve an important role in 
carcinogenesis (Samuels et al., 2004) regulating cell growth, differentiation, survival, 
proliferation and migration  and mutations in PIK3CA, the gene encoding 
phosphatidylinositol-4,5-bisphosphonate 3-kinase catalytic subunit alpha polypeptide, are 
present in 15-20% of colorectal cancers (Barault et al., 2008, Liao et al., 2012, Whitehall et 
al., 2012).  The up-regulation of PI3K enhances prostaglandin-endoperoxide synthase 2 
(PTGS2) also known as COX-2, and therefore PGE2 synthesis leading to inhibition of 
apoptosis in colon-cancer cells (Kaur and Sanyal, 2010).  Studies have shown that aspirin 
may suppress cancer cell growth by blocking the PI3K pathway and inducing apoptosis 
(Uddin et al., 2010).  Furthermore, regular aspirin use after diagnosis of colorectal cancer was 
associated with longer survival in those patients with mutated PIK3CA colorectal cancer 
(Kang et al., 2013).  
The direct tumoral effects of the PI3K pathway include inhibition of apoptosis, 
increased cellular proliferation and growth and a reduction in cell-cycle arrest (Le and Fodde, 
2008).  The PI3K pathway is involved in the function of leukocytes and endothelial cells and 
they appear to be crucial mediators of inflammatory reactions (Le and Fodde, 2008).  As a 
vital signalling pathway in the innate immune response, PI3K is involved in chemotaxis of 
neutrophils and macrophages to the site of inflammation (Morrison et al., 2012) and this may 
be another mechanism by which it is involved in carcinogenesis. 
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Cyclo-oxygenase 
Cyclo-oxygenase-2 (COX2) is an inducible mediator of prostaglandin synthesis and the 
pro-neoplastic effects of COX2 are mediated by the prostanoid PGE2, its major end product.  
COX2 has been shown to be over-expressed in colorectal cancers (Sheehan et al., 1999, 
Dimberg et al., 1999) as has PGE2 (Taketo, 1998, Kawamori et al., 2003) and its expression 
is associated with tumour invasiveness and metastatic potential (Church et al., 2003, Fujita et 
al., 1998, Tsujii et al., 1997).  Much of the evidence describing the role of COX-2 in 
carcinogenesis derives from observing the actions of COX-2 inhibitors. The direct tumoral 
effects of COX-2 inhibitors may be related to the inhibition of COX-mediated synthesis of 
PGE2, which has been shown to increase tumour cell proliferation, decrease apoptosis, 
increase angiogenesis and increase chemo- and radio-resistance (Park et al., 2014).  The 
interactions between tumour and host cells are mediated by growth factors and cytokines, 
which act as paracrine factors for endothelial and stromal cells (Tanaka et al., 2012).  Non-
steroidal anti-inflammatory drugs (NSAIDs) have been shown to decrease serum markers of 
inflammation including C-reactive protein (CRP), interleukin-6 (IL-6) and tumour necrosis 
factor-α (TNF-α) in patients with advanced cancer (Senovilla et al., 2012). 
 Cyclo-oxygenase inhibitors have therefore been proposed as an option for 
chemoprevention of colorectal cancer.  Both selective inhibitors (such as celecoxib) and 
nonspecific inhibitors (for example aspirin) reduced the incidence of colorectal cancer 
(Flossmann et al., 2007, Chan et al., 2005) and the incidence of and recurrence of 
adenomatous polyps, established as precursors of colorectal cancer, were inversely associated 
with the regular use of NSAIDs (Tangrea et al., 2003, Johnson et al., 2010). 
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Moderation of the Inflammatory Response in Colorectal Cancer 
 
Attempts have been made to manipulate the inflammatory response in colorectal 
cancer and there is epidemiological evidence to support the roles of lifestyle, medication use 
and diet in colorectal cancer risk and its prevention (Chan and Giovannucci, 2010).   
A recent meta-analysis found that aspirin use is associated with a pooled risk ratio of 
0.83 (95% CI, 0.72-0.96) for any adenoma and 0.72 (95% CI, 0.57-0.90) for advanced 
adenomas (Cole et al., 2009) although there was evidence of between-study heterogeneity 
(I
2
-= 60.1% for any adenoma and 65.4% for advanced lesions).  Other randomised control 
trials found that long-term use of aspirin protects against colorectal cancer in a dose-
dependent manner (Flossmann et al., 2007).  There have been many observational studies 
supporting the role of non-aspirin and non-COX-2 selective NSAIDs in colorectal cancer 
prevention; however, randomised trial data are limited.  The most compelling hypothesis on 
the proposed mechanisms by which NSAIDs  reduce the risk of colorectal neoplasia is related 
to their anti-inflammatory effect via the inhibition of COX-2.  Moderation of the 
inflammatory response with medications such as aspirin and non-steroidal anti-inflammatory 
drugs are associated with substantial reductions in colorectal cancer risk although their utility 
may be affected by the associated risks and side-effect profile such as bleeding, peptic 
ulceration and cardiovascular events with COXIBs . 
The role of environmental factors in the development of colorectal cancer is supported 
by the global variation in the incidence of CRC and its change on migration (Ladabaum et al., 
2014).  Many of the lifestyle risk factors associated with CRC including obesity, low levels 
of physical activity, alcohol consumption and smoking are associated with the activation of 
one or more of the above inflammatory pathways.  An inverse association between levels of 
physical activity and the risk of colon cancer has been one of the most consistently observed 
13 
 
(Colbert et al., 2001, Colditz et al., 1997) with a recent meta-analysis demonstrating that 
physically active individuals had a 20-30% lower risk of colon cancer compared to less active 
individuals (Wolin et al., 2009). The mechanisms by which physical activity reduces the risk 
of CRC are not yet fully understood, however, it may be in part due to a reduction in systemic 
inflammation which is largely mediated through the inhibition of COX-2 (Chan and 
Giovannucci, 2010). 
The second World Cancer Research Fund/American Institute for Cancer Research 
(WCRF/AICR) report advised that there is convincing evidence that red meat and processed-
meat intake and higher alcohol intake are associated with a higher colorectal cancer risk 
whilst dietary fibre is associated with a lower risk. The evidence that milk and calcium as 
well as non-starchy vegetables, fruit and fish are associated with a lower risk of colorectal 
cancer is less convincing.  Whilst there are several suggested mechanisms by which alteration 
of dietary intake may act to reduce the risk of colorectal cancer, including anti-oxidant and 
gut modulatory properties, an anti-inflammatory effect exerted by certain dietary compounds 
appears to play an important role.  
Another mechanism by which dietary components may be linked to the development of 
colorectal cancer may involve the intestinal microbiota. Several studies have found 
differences in the population of bacteria in those with and those without CRC (Azcarate-Peril 
et al., 2011) and intestinal microbes may act as pro-carcinogens by inducing pro-
inflammatory cytokines, whilst dietary modification can alter the number and type of micro-
organisms present.  
 
Polyphenols and cancer associated inflammation 
Polyphenols are phytochemicals abundant in plant foods and can be considered as 4 
main classes: flavonoids, phenolic acids, stilbenes and lignans.  Polyphenolic compounds are 
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characterised by a benzene ring with one or more hydroxyl groups attached and can be 
isolated from plant sources including fruits and vegetables, berries and seeds and some 
beverages such as tea, green tea, red wine and coffee.    Dietary polyphenols have been 
shown to have anti-carcinogenic and anti-inflammatory effects through various mechanisms 
involving signalling cascades and transcription factors (Marzocchella et al., 2011).   
  The biological effects of polyphenols that contribute to their role in the inhibition of 
carcinogenesis include anti-oxidant, anti-inflammatory and phytoestrogenic properties and an 
ability to inhibit cellular proliferation, invasion, angiogenesis and metastasis and promote 
apoptosis  (Qu et al., 2005, Danbara et al., 2005).     
Flavonoids are ingested as part of a normal diet and it is therefore logical that they have 
been suggested to play a role in the modulation of intestinal inflammation.  The 
bioavailability of polyphenolic compounds is low and therefore they remain in the lumen 
where they are degraded and metabolised by gut bacteria to phenolic metabolites.  
Administration of polyphenols was effective at preventing and treating intestinal 
inflammation in rodents models of IBD where acute or chronic colitis was induced by intra-
rectal administration of dinitrobenzene sulphate (Oz et al., 2005, Kim et al., 2005) and 
addition of dextran sulphate sodium (DSS) to drinking water (Camuesco et al., 2004).   
Several in vivo animal studies have been performed with naturally occurring 
polyphenols demonstrating their therapeutic effects in different disease models, particularly 
those with where an inflammatory component is pertinent.  One such example is Rheumatoid 
Arthritis, and various flavonoids and related polyphenols have been demonstrated to reduce 
arthritis induced inflammation (Wang et al., 2008, Elmali et al., 2007, Tang et al., 2007).  
Cardiovascular disease is another condition which evidence suggests is prevented by dietary 
polyphenolic compounds and the mechanisms by which they exert this action appears to be at 
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least in part anti-inflammatory because the levels of ICAM-1 and VCAM-1 in atherosclerotic 
blood vessels were reduced (Gonzalez et al., 2011).   
Although the literature is still lacking evidence from trials involving human subjects, 
several human studies have reported that polyphenolic compounds may reduce the secretion 
of pro-inflammatory cytokines (Chun et al., 2008, Bobe et al., 2010a) and the molecular 
mechanisms by which polyphenols may exert their anti-inflammatory effects are multiple 
including the attenuation of signal transduction pathways, the cyclooxygenase and 
lipooxygenase pathways in particular (Wang et al., 2006).  
In the context of benign inflammatory disease, a 6-month placebo-controlled trial of 
curcumin therapy in 89 patients with quiescent ulcerative colitis (UC) found a decreased 
relapse rate in those who were treated with curcumin (Hanai et al., 2006).  Relapse was seen 
in 5% of those treated with curcumin and 21% of the placebo group. 
Of the entire gastrointestinal tract, the large intestine may be exposed to the highest 
concentration of flavonoids due to their poor availability (Halliwell et al., 2000) and there is a 
growing body of evidence from human studies that certain polyphenolic compounds are 
associated with a reduced risk of colorectal cancer (Rossi et al., 2006, Theodoratou et al., 
2007).  Furthermore, case-control studies comparing dietary polyphenol intake in those 
diagnosed with colorectal cancer, with a control group, using food frequency questionnaires 
have demonstrated that the consumption of certain polyphenols was low in CRC cases versus 
controls and these are outlined in Table 2.  
This presents an interesting concept, that dietary alteration to a diet high in polyphenols 
such as fruits and vegetables, berries, tea and coffee may be effective in modulating 
inflammatory responses and therefore decreasing the risk of advanced and high-risk 
colorectal adenoma recurrence (Bobe et al., 2010a, Bobe et al., 2008) and colorectal cancer 
(Rossi et al., 2006, Theodoratou et al., 2007) without the adverse effects that have been 
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associated with some of the agents currently under investigation for chemoprevention in 
colorectal carcinogenesis. 
 
The effect of polyphenols on signal transduction pathways important in tumour growth 
and inflammation in CRC 
The anti-inflammatory activities of polyphenols can be related to the arachidonic acid-
dependent pathway (COX, lipo-oxygenase and phospholipase A2 inhibition) or arachidonic 
independent pathways involving nitrous oxide synthase (NOS), NF-κB and NAG (Biesalski, 
2007).  Despite this, the evidence for polyphenols as anti-inflammatory agents remains 
limited and most studies have been performed in vitro and have concentrated on one specific 
polyphenolic compound (Table 1).  
 
NF-kB  
Dietary polyphenols such as resveratrol (Manna et al., 2000), green tea catechins (Yang 
et al., 2001) and curcumin (Singh and Aggarwal, 1995) are potent inhibitors of the NF-κB 
signalling pathway in human and animal cell lines in vitro and the mechanisms by which they 
exert this effect are becoming better understood.  These substances may intervene at any step 
in the NF-κB signalling pathway, for example, inhibition of the translocation of NF-κB to the 
nucleus or inhibition of any of the initial stimulatory signal transduction pathways or 
transcription factors.  Curcumin (the main polyphenolic in turmeric) is one such example 
which has been shown to mediate its chemotherapeutic effects by NF-κB inhibition and by 
inhibition of NF-κB regulated gene products such as COX-2, adhesion molecules, MMPs, 
iNOS, Bcl-2 and TNF (Shishodia et al., 2005). 
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STAT 
Dietary polyphenols epigallocatechin-3-gallate (EGCG) from green tea (Masuda et al., 
2001), resveratrol (Wung et al., 2005) and curcumin (Bharti et al., 2003) have been shown to 
suppress the activation of STAT in tumour cells in human malignancy.  EGCG was shown to 
down-regulate the phosphorylation of STAT3 whilst resveratrol inhibited IL-6 induced 
ICAM-1 gene expression partly by interfering with STAT3 phosphorylation.  
 
PI3k 
There is little in the way of evidence to support the inhibition of PI3k by polyphenolic 
compounds.  Li et al demonstrated down-regulation of the oncogene MDM2  by curcumin  
via the PI3K signalling pathway and when activated, this pathway is known to promote cell 
survival and proliferation (Li et al., 2007).  This effect was noted in human cancer cell lines 
as well as normal cell lines.  Further work on colorectal cancer cells treated with curcumin 
demonstrated an inhibitory effect on cell growth in a time and dose-dependent manner via the 
PI3k/Akt pathway (Johnson et al., 2009).  
Another polyphenol, quercetin, has been shown to exert a protective effect against 
COX-2 expression and PGE2 production by targeting the PI3K signalling pathway in rat liver 
epithelial cells and this may contribute to its chemopreventive potential (Lee et al., 2010). 
 
Cyclo-oxygenase 
Dietary polyphenols have been shown to exert their anti-inflammatory effects through 
inhibition of COX-2 at the transcriptional and enzyme level (Biesalski, 2007).  Many dietary 
polyphenols have demonstrated this ability to inhibit COX-2 in vitro including green tea 
18 
 
extract enriched with catechin and epigallocatechin gallate (EGCG) which inhibited COX-2 
expression in mouse skin (Kundu et al., 2003) and genistein, quercetin, kaempferol and 
resveratrol were found to down-regulate COX-2 promoter activity in human colon cancer 
cells (Mutoh et al., 2000). 
NSAID activated gene-1 is a member of the TGF-β superfamily proteins and is another 
factor involved in the inflammatory response.  It is activated by NSAIDs and also by several 
dietary compounds.  Induction of NAG-1 can induce apoptosis and promote anti-tumorigenic 
activity (Baek et al., 2004).  Baek et al have demonstrated that green tea polyphenol, 
epicatechin gallate, induces the expression of NAG-1 in colon cancer cells (Baek et al., 
2004). 
Table 1: Mechanisms of chemoprevention by polyphenols in in vitro cell lines 
Authors Cell Type Poyphenol (s) Outcomes  
Kundu et al (2003) 
(Kundu et al., 2003) 
Mouse skin Catechin 
Epigallocatechin gallate 
Inhibition of COX-2 expression 
Mutoh et al (2000) 
(Mutoh et al., 2000) 
Human colon cancer 
DLD-1 cells 
Quercetin, kaempferol, 
genistein, resveratrol, 
resorcinol 
Inhibition of COX-2 expression 
Suh et al (2009)          
(Suh et al., 2009) 
 
 
Human colon cancer 
HT29 cells 
Fisetin Apoptosis & down regulation of 
COX-2 protein expression in 
colon cancer cells 
Li et al (2007)                
(Li et al., 2007) 
Human prostate cancer 
cell lines 
Curcumin Reduced oncogene MDM2 via 
PI3K signalling 
Johnson et al (2009) 
(Johnson et al., 2009) 
Colorectal cancer cells Curcumin Inhibitory effect on cell growth 
via PI3K/Akt pathway 
Lee et al (2010)            
(Lee et al., 2010) 
Rat liver epithelial 
cells 
Quercetin Protective effect of quercetin 
against COX-2 expression by 
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targeting PI3K 
Manna et al (2000) 
(Manna et al., 2000) 
Human cells lines 
(lymphoma, epithelial 
cells) 
Resveratrol Inhibition of TNF induced 
activation of NF-κB 
Singh et al (1995)    
(Singh and Aggarwal, 
1995) 
Human leukaemia cell 
line 
Curcumin Inhibition of NF-κB 
Yang et al (2001)     
(Yang et al., 2001)  
Rat intestinal epithelial 
cell line 
ECGC Inhibition of I kappa B kinase 
complex mediated activation of 
NF-κB 
Bharti et al (2003)  
(Bharti et al., 2003) 
Human malignant 
melanoma cell lines 
Curcumin Inhibition of IL-6 induced 
STAT3 phosphorylation 
Masuda et al         
(Masuda et al., 2001) 
Head and neck 
squamous cell 
carcinoma cell line 
EGCG Suppression of the activation of 
STAT3 
Wung et al (2005)  
(Wung et al., 2005) 
Bovine aortic 
endothelial cells 
Resveratrol Inhibition of phosphorylation 
and of activation of STAT3 
Baek et al (2004)     
(Baek et al., 2004) 
Human colon cancer 
cells (HCT-116) 
Catechins ECG induced expression of 
NAG-1 
Martinez-Florez et al 
(2005)               
(Martinez-Florez et 
al., 2005)  
Rat hepatocytes 
 
Quercetin Inhibition of iNOS expression by 
quercetin 
 
Polyphenols & the systemic inflammatory response 
Cytokine concentrations measured in the serum or in the tumour itself may be utilised 
as markers of inflammation and may be an indicator of the risk of neoplastic change or 
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progression (Pellegrini et al., 2006).  In human studies, elevated serum levels of IL-6, CRP 
and TNF-α were associated with the presence of colorectal adenomas (Kim et al., 2008).  
Interleukin-6 
Interleukin-6 is a pro-inflammatory cytokine, the primary source of which are 
monocytes and macrophages during acute inflammation and T cells during chronic 
inflammation and it may act as a tumour promoter in colorectal neoplasms (Naugler and 
Karin, 2008, Heikkila et al., 2008).  Activation of IL-6 activates Janus kinases (JAK) and 
STATs, which are involved in the regulation of cell proliferation and apoptosis (Hodge et al., 
2005).  There is a growing body of evidence that IL-6 is over-expressed in colorectal cancer 
tissue (Chung et al., 2006, Kinoshita et al., 1999) and, further to this, increased 
concentrations of IL-6 were associated with poorer survival and high-risk pathological factors 
such as T-stage, nodal status and vascular invasion (Chung et al., 2006).  Similarly, there is 
reliable evidence that circulating concentrations of IL-6 are elevated in patients with 
colorectal cancer when compared to normal controls and, again, this is associated with poorer 
survival, tumour size and T-stage (Belluco et al., 2000, Galizia et al., 2002, Chung and 
Chang, 2003, Nikiteas et al., 2005).  In addition to colorectal adenocarcinoma, IL-6 
concentrations were also associated positively with the presence of colorectal adenoma in a 
colonoscopy-based study in North Carolina (Kim et al., 2008).   
The evidence in humans that the consumption of dietary polyphenols decreases 
circulating levels of inflammatory markers such as IL-6 remains inconclusive (Song et al., 
2005, Chun et al., 2008).  Recently, Bobe et al (Bobe et al., 2010a) investigated whether 
serum IL-6 was associated with colorectal adenoma recurrence and flavonol intake in order to 
determine whether measuring serum levels would serve as an indicator of risk or recurrence.  
They found that a high intake of flavonols was inversely associated with serum IL-6 
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concentrations and advanced  and high risk adenoma recurrence and concluded that dietary 
flavonols could serve as a method to prevent colorectal cancer and that serum IL-6 levels 
may serve as an indicator of risk and of response (Bobe et al., 2010a).  
CRP 
C-reactive protein is a nonspecific marker of systemic inflammation and it has been 
widely used to detect and monitor systemic inflammatory responses with extensive research 
supporting the fact that CRP levels are higher in cancer patients than healthy subjects.  
Several large cohort studies have identified a link between pre-cancer inflammation as 
measured by the CRP and colorectal cancer risk (Prizment et al., 2011, Allin et al., 2009). 
Furthermore, the systemic inflammatory response measured by circulating CRP levels, is a 
predictor of recurrence and overall survival in those with colorectal cancer.  
 Population-based observational and randomised control trials have found that an 
inverse relationship between the serum CRP concentration and dietary intake of substances 
high in polyphenols exists (De Bacquer et al., 2006, Steptoe et al., 2007, Chun et al., 2008). 
Chun et al (Chun et al., 2008) analysed the dietary flavonoid intakes of over 8000 American 
adults. Total flavonoid and individual flavonoid compounds (quercetin, kaempferol, 
malvidin, peonidin, daidzein and genistein) had inverse associations with serum CRP 
concentration. 
TNF 
TNF is produced during the initial inflammatory response, initiating the production of 
cytokines and chemokines and increasing vascular permeability therefore promoting  
inflammation, angiogenesis and tumour dissemination (Li et al., 2009, Balkwill, 2009).  Its 
expression increases during colon tumorigenesis and interference with TNF signalling with a 
soluble decoy receptor decreased tumorigenicity and tumour growth (Popivanova et al., 
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2008).  Polyphenol ellagic acid has been shown to reduce the expression of COX-2, iNOS, 
IL-6 and TNF-α in a rat model of colon cancer (Umesalma and Sudhandiran, 2010).  
Other studies have reported that concentrations of IL-8, IL-10, IL-12, granulocyte 
macrophage colony stimulating factor (GMCSF) and TNF-α are higher in those individuals 
with colorectal adenomas (Berghella et al., 1997) however, more recent studies were unable 
to associate serum concentration of IL-1, 2, 8, 10, GM-CSF, IF-ɣ or TNF-α with an elevated 
risk of colorectal adenoma recurrence, despite decrease cytokine concentrations during high 
flavonol consumption (Bobe et al., 2010b). 
 
 
Figure 2: Mechanisms of inhibition of inflammation in cancer by dietary polyphenols  
Signal transducer and activation of transcription 3 (STAT3) and nuclear factor-kβ (NF-Kβ) are induced in 
cancer cells by pro-inflammatory cytokines. This results in the suppression of apoptosis and the promotion of 
cell cycle progression and cell proliferation. Various dietary polyphenolic compounds have been demonstrated 
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to inhibit these inflammatory pathways (  ), ultimately reducing cancer-associated inflammation and 
therefore reducing the incidence of neoplasia. 
 
 
Dietary Polyphenols and Colorectal Neoplasia Risk in Observational Studies 
There is epidemiological evidence from a limited number of case-control and cohort 
studies (Table 2), which have assessed the relationship between dietary flavonoid intake and 
colorectal cancer or colorectal adenomas.  Flavonols are one class of dietary polyphenols that 
have been investigated for their ability to reduce the risk of colorectal adenoma recurrence in 
the Polyp Prevention Trial (Bobe et al., 2008).  Bobe and colleagues found that a higher 
intake of flavonols was associated with a 76% decrease in the risk of advanced adenoma 
recurrence.  They hypothesised that this may also apply in colorectal adenocarcinoma given 
that in cell culture more progressed tumour cells were more sensitive to flavonols (Jeong et 
al., 2009).  
 
Table 2: Clinical studies reporting an association between intake of dietary polyphenols 
and colorectal cancer/adenoma risk 
 
Authors Sample 
Size 
Methods Outcomes Association Strength of 
Association 
Akhter et al 
(2008) 
(Akhter et 
al., 2008) 
886 Prospective 
cohort study 
Association of isoflavone 
intake with CRC risk 
Intake of 
isoflavones is 
associated with 
reduced risk of 
proximal colon 
cancer in men 
only 
HR in highest 
quartile 0.55 (5% 
CI 0.33-0.92) for 
proximal cancer in 
men only (P= 
0.007) 
Akhter 
(2009) 
(Akhter et 
al., 2009) 
721 
cases 
697 
controls 
Case-control 
study 
Association of isoflavone 
intake & colorectal 
adenoma risk 
There is an 
inverse 
association 
between dietary 
isoflavone intake 
and colorectal 
OR 0.7 (95% CI 
0.51-0.96) for 
highest vs lowest 
quartile of 
isoflavone intake 
P=0.03 overall and 
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adenoma and it 
was more 
pronounced in 
women 
0.49 (0.27-090) in 
women (P=0.03) 
Arts (2002) 
(Arts et al., 
2002)  
33,339 
(635 
colon 
cancers) 
Cohort study Association of dietary 
catechin intake and 
cancer incidence amongst 
postmenopausal women 
Rectal cancer but 
not colon cancer 
was inversely 
associated with 
catechin intake 
RR 0.55 for highest 
quartile of intake 
(P= 0.02) for rectal 
cancer only 
Bobe (2008) 
(Bobe et al., 
2008) 
958 
cases 
947 
controls 
Randomised, 
multicentre 
nutritional 
intervention 
trial 
Association of flavonoids 
with adenoma recurrence 
High intake of 
flavonols and 
isoflavonoids 
were associated 
with reduced 
incidence of 
advanced 
adenoma 
recurrence 
OR 0.24 (95% CI 
0.11-0.53) for 
highest vs lowest 
quartile for 
flavonols 
(P=0.0006) & 0.46 
(0.22-0.95) for 
isoflavonoids 
(P=0.01) 
Budhathoki 
(2011) 
(Budhathoki 
et al., 2011) 
816 
cases 
815 
controls 
Case-control 
study 
Association of soy food 
and isoflavone intake and 
CRC risk 
High intake of 
soy food and 
isoflavones were 
inversely 
associated with 
colorectal cancer 
risk in men and 
post-menopausal 
women 
OR for highest vs 
lowest quintile 0.65 
(95% CI 0.41-1.03), 
p=0.03 for soy 
foods & 0.68 (0.42-
1.10) p= 0.051 for 
isoflavones in men 
& 0.60 (0.29-1.25) 
p=0.053 & 0.68 
(0.33-1.40) p= 
0.049 in 
postmenopausal 
women 
Cotterchio 
(2006) 
(Cotterchio 
et al., 2006) 
1095 
cases 
1890 
controls 
Case-control 
study 
Association of dietary 
phytoestrogens and 
colorectal cancer risk 
Dietary lignan 
and isoflavone 
intake were 
associated with 
reduced risk of 
colorectal cancer 
OR 0.73 (95% CI 
0.56-0.94) p= 
0.01for highest vs 
lowest lignan intake 
& 0.71 (0.58-0.86) 
p<0.01 for 
isoflavones 
Djuric 
(2012) 
(Djuric et al., 
2012) 
1163 
cases 
1501 
controls 
Case-control 
study 
Association of dietary 
intake of quercetin and 
risk of colorectal cancer 
Protective 
effective of 
quercetin on risk 
of proximal 
colon cancer 
only when fruit 
intake high and 
tea intake low 
OR 0.49 (95% CI 
0.32-0.73) P=0.006) 
with high fruit 
intake, 0.44 (0.27-
0.72) P= 0.003with 
high healthy eating 
index & 0.51 (0.26-
1.00) P=0.044 when 
tea intake was low 
Kyle (2010) 
(Kyle et al., 
2010) 
264 
cases 
408 
controls 
Case-control 
study 
Evaluation of the 
association of four 
flavonoid subclasses and 
the risk of colorectal 
cancer 
Non-tea flavonol, 
specifically 
quercetin were 
associated with 
reduced 
colorectal cancer 
risk 
OR 0.6 (95% CI 
0.4-1.0) for non-tea 
flavonol  & 0.5 
(0.3-0.8) P<0.01 for 
colon cancer with 
high levels of non-
tea quercetin intake 
Rossi (2006) 
(Rossi et al., 
2006) 
1953 
cases 
4154 
controls 
Case-control 
study 
Association of flavonoid 
intake and colorectal 
cancer risk 
Reduced risk 
colorectal cancer 
with high intake 
isoflavones, 
anthocyanidins, 
flavones, 
OR 0.76 (95% CI 
0.63-0.91) P=0.001 
for isoflavones, 
0.67 (0.54-0.82) 
P<0.001 for 
anthocyanidins, 
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flavonols 0.78 (0.65-0.93) 
P=0.004 for 
flavones, 0.64 
(0.54-0.77) P<0.001 
for flavonols 
Simons 
(2009) 
(Simons et 
al., 2009) 
2485 
cases 
Cohort study Association of flavonol, 
flavones & catechin 
intake with CRC risk 
Total catechin 
and epicatechin 
intake was 
associated with 
rectal cancer in 
men with 
BMI>25 and 
total catechin, 
kaempferol, 
myricetin was 
associated with 
colorectal cancer 
in women 
BMI<25 
Total 
catechin/epicatechin 
in male rectal 
cancer with 
BMI>25 HR 0.63 
(0.36-1.08) P=0.04. 
Total catechin in 
female colon cancer 
with BMI<25 HR= 
0.62 (0.43-0.91) 
P=0.04 for highest 
vs lowest quintiles 
Theodoratou 
(2007) 
(Theodoratou 
et al., 2007) 
1456 
cases 
1456 
controls 
Case-control 
study 
Association of flavonoid 
intake with CRC risk 
Increased 
consumption of 
flavonols, 
quercetin, 
catechin & 
epicatechin were 
associated with a 
reduction in 
colorectal cancer 
risk 
OR 0.73 P=0.0121 
for flavonols, 0.68 
P=0.001 for 
quercetin, 0.68 
P<0.0005 for 
catechin, 0.74, 
P=0.019 for 
epicatechin & 0.78 
P=0.031 for 
procyanidins. 
Ward (2010) 
(Ward et al., 
2010) 
221 
cases 
886 
controls 
Case-control 
study 
Association of risk of 
colorectal cancer relative 
to phyto-oestrogen intake 
Colorectal cancer 
risk was 
inversely 
associated with 
enterolactone & 
entrolignans in 
women only 
OR 0.33 (0.14-0.74) 
P=0.008 for 
enterolactone & 
0.32 (0.13-0.79) 
P=0.013 for 
enterolignans 
Yang, G 
(2009) 
(Yang et al., 
2009) 
68412 
(321 
CRC) 
Cohort study The relationship between 
intake of soy 
foods/isoflavones and 
colorectal cancer risk 
Soy 
foods/isoflavones 
reduced the risk 
of colorectal 
cancer in 
postmenopausal 
women 
RR 0.67 (95% CI 
0.49-0.90) for 
highest vs lowest 
tertile p=0.008 
Zamora-Ros 
(2013) 
(Zamora-Ros 
et al., 2013)  
424 
cases 
401 
controls 
Case-control 
study 
Relationship between 
dietary flavonoid and 
lignin intakes and the risk 
of colorectal cancer 
Intake of total 
dietary 
flavonoids and 
lignans was 
inversely 
associated with 
colorectal cancer 
risk 
OR 0.59 95% CI 
0.35-0.99) for 
flavonoids P=0.04, 
0.59 (0.34-0.99) for 
lignans P=0.03 
 
Hoensch and colleagues investigated the recurrence risk of neoplasia in patients with resected 
colorectal cancer and after polypectomy in those who were treated with a mixture of 
flavonoids (apigenin and epigallocatechin-gallate) as compared to a matched control group.  
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36 patients had resected colon cancer and 51 had undergone polypectomy (Hoensch et al., 
2008).  Both the treated group and the untreated controls were monitored with a surveillance 
colonoscopy for 3-4 years and also by questionnaire.  The combined recurrence rate for 
neoplasia (cancer and adenoma) was 7% in the treated group compared to 47% in the control 
group.  Therefore, they concluded that treatment with flavonoids could reduce the recurrence 
rate of neoplasia in those with resected colon cancer. 
 
Conclusion 
Over the past decade there has been an increased appreciation that inflammation has a 
significant role to play in human carcinogenesis and there is a significant body of evidence to 
support the role of the host inflammatory response in the progression of cancer of the colon 
and rectum.  Various methods of favourably manipulating cancer-associated inflammation 
have shown promise including aspirin, statins and other non-steroidal anti-inflammatory 
drugs.  Lifestyle factors also play a role in the development of colorectal cancer including 
obesity, lack of exercise, alcohol consumption and dietary intake.  Further to this, dietary 
polyphenolic compounds have been shown to act at multiple key steps in carcinogenesis and 
therefore a role in colorectal cancer prevention has been suggested. 
The current evidence from epidemiological studies on the association of dietary 
flavonol intake and colorectal cancer or adenoma risk is limited and much of the current 
research concentrates on isolated flavonoids.  Although positive associations between a 
reduction in risk and many polyphenolic compounds have been demonstrated, the data is 
inconsistent and many find this positive association with only one compound out of several 
tested.  
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As there are relatively few human studies at the time of writing conferring the benefit 
of a diet rich in polyphenols in those who have colorectal adenomas or adenocarcinoma, it 
would be premature to suggest a major public health intervention to promote their 
consumption.  However, dietary change is both safe and feasible and this emphasises the need 
for further investigation of dietary polyphenols and their association with colorectal cancer 
risk.  This data would be essential in formulating dietary recommendations for the general 
public and for those who are at an increased risk of colorectal adenoma or carcinoma and this 
may complement the current bowel screening programme to work towards a shift to earlier 
stage diagnosis of colorectal cancer.  
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